The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
Open accessAbstract
Purpose: To report the impact of radiotherapy quality on outcome in a large international phase III trial evaluating radiotherapy with concurrent cisplatin plus tirapazamine for advanced head and neck cancer. Patients and Methods: The protocol required interventional review of radiotherapy plans by the Quality Assurance Review Center (QARC). All plans and radiotherapy documentation underwent post-treatment review by the Trial Management Committee (TMC) for protocol compliance. Secondary review of noncompliant plans for predicted impact on tumor control was performed. Factors associated with poor protocol compliance were studied, and outcome data were analyzed in relation to protocol compliance and radiotherapy quality. Results: At TMC review, 25.4% of the patients had noncompliant plans but none in which QARC-recommended changes had been made. At secondary review, 47% of noncompliant plans (12% overall) had deficiencies with a predicted major adverse impact on tumor control. Major deficiencies were unrelated to tumor subsite or to T or N stage (if N+), but were highly correlated with number of patients enrolled at the treatment center (< five patients, 29.8%; ≥ 20 patients, 5.4%; P < .001). In patients who received at least 60 Gy, those with major deficiencies in their treatment plans (n = 87) had a markedly inferior outcome compared with those whose treatment was initially protocol compliant (n = 502): −2 years overall survival, 50% v 70%; hazard ratio (HR), 1.99; P < .001; and 2 years freedom from locoregional failure, 54% v 78%; HR, 2.37; P < .001, respectively. Conclusion: These results demonstrate the critical importance of radiotherapy quality on outcome of chemoradiotherapy in head and neck cancer. Centers treating only a few patients are the major source of quality problems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Self-citationKhalil, A. A., Bentzen, S. M., Bernier, J., Saunders, M. I., Horiot, J.-C., den Bogaert, W. F. V., Cummings, B., & Dische, S. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03790-2 · Cited by 53
Self-citationEORTC Radiotherapy Group: achievements and future projects
Budach, V., Zurlo, A., & Horiot, J.-C. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00440-3 · Cited by 14
Cited by
Expanding global access to radiotherapy
Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M., Lievens, Y., Lui, T. Y. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00222-3 · Cited by 1,112
Self-citationRischin, D., Young, R. J., Fisher, R., Fox, S. B., Le, Q.-T., Peters, L. J., Solomon, B., Choi, J., O'Sullivan, B., Kenny, L. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2904 · Cited by 737
Self-citationImage-guided radiotherapy: from current concept to future perspectives
Jaffray, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.194 · Cited by 496
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Overgaard, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.03.004 · Cited by 456
Metadata
- Authors
- Peters, L. J., O'Sullivan, B., Giralt, J., Fitzgerald, T. J., Trotti, A., Bernier, J., Bourhis, J., Yuen, K., Fisher, R., & Rischin, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-06-20
- Volume
- 28
- Issue
- 18
- Pages
- 2996-3001
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161501889
- Cited by
- 812
- References
- 3
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.